Sign in
Taking people in New ZealandPhase 1

Tests safety of plamotamab in adults with rheumatoid arthritis

Tests plamotamab's safety in adults with rheumatoid arthritis.

Key facts

Who runs it
Xencor, Inc.
Where
Auckland, New ZealandSee the siteAlso in 2 other countries, 2 sites
Trial code
Registry title
A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
Status
Recruiting
Phase
Phase 1
People taking part
68 people, planned
Started
21 Oct 2025
Expected to end
Jun 2028
Type of study
Interventional
Treatments tested
  • Plamotamab
Record updated
3 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderately to severely active rheumatoid arthritis. It tests the safety of plamotamab, given as an injection under the skin.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Moderately to severely active rheumatoid arthritis (RA), diagnosed at least 3 months before screening.
Earlier treatment
Inadequate response, loss of response or intolerance to available RA therapies. Stable doses of RA medicines before screening.

Main reasons for not taking part

  • Major surgery within 12 weeks before screening or planned within 12 months after dosing
  • Recurrent infections or an active, clinically significant infection
  • Active or untreated latent tuberculosis
  • Cancer or lymphoproliferative disease within the previous 5 years
  • Uncontrolled heart, lung, kidney, liver, hormone or gut disease

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening
  • Inadequate response to, loss of response to, or intolerance to available RA therapies
  • Stable doses of RA medications prior to screening
  • Use of highly effective methods of contraception

Who cannot take part

  • Major surgery within 12 weeks prior to screening or planned within 12 months after dosing
  • Recurrent infections or active clinically significant infection
  • Active or untreated latent tuberculosis
  • Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
  • Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease; Note: Additional, more specific inclusion/exclusion criteria are defined in the protocol

This trial is currently available in New Zealand.

Also in 2 other countries, 2 sites

  • AucklandHospital not named in the registryTaking people

About the trial

What the trial wants to find out

The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.

The group in the trial

  • Dose EscalationTreatment being tested

    Plamotamab administered SC

    Treatment: Plamotamab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis
Plain-language title
Tests safety of plamotamab in adults with rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 August 2026